RE:A new lexicon for specialty pharmasSelect, Ashely Misquitta of Mackenzie Investments spoke to the very point you have made on Business News A.M. reiterating that the narrative of pharma companies must be postioned in relation to patients, physicians, scientists, etc. Only then can politicians pretend that they have fixed the system and flamed the Skhreli's and the Valeants. If Concordia refuses to change its mantra, it will just be added to the list.
Whether you owned or have ever owned Valeant, investment houses around the world are paying attention.... as you just don't see large caps crumble like this. Mark Thompson must change his linguistic perspective or down we will go. Select, I would like to add the words "innovation" on your list of phrases that are "in" (and up). Investors are looking to pharma companies that can make a difference in the lives of people, not line the pockets of MT (at the expense of shareholders) so he can jetset.
Share price will be the final arbiter of the variant views expressed yesterday and today on this subject.
select1011 wrote: Sometimes it is about communications and here are my own views about how the language from spec pharmas needs to change. The following words and phrases are out: "strategic platform, M&A, accretive, roll-up, orphaned drugs, pricing advantage, lean, debt" The following words and phrases are in: "organic growth, patient focussed, physician partnered, public program partnered. transparent, compliant, global, responsive, R&D. Many new biotechs and pharmas were created out of deal making, and their CEOs still speak the deal making lingo. To the extent that renewed trust is needed in these managers, they need to rebalance there language, tell different stories (I don't want to hear the living room story from MT anymore), and talk up patient service, and health system partnerships. Less swagger, more about what matters. All my two cents.